Company Overview and News

 
Coats Group Plc ADR 2017 Q4 - Results - Earnings Call Slides

2018-02-28 seekingalpha
The following slide deck was published by Coats Group plc ADR in conjunction with their 2017 Q4 earnings call.
Upvote Downvote

 
Total Voting Rights

2017-08-01 londonstockexchange
Coats Group plc, the world's leading industrial thread manufacturer, in conformity with Rule 5.6.1 of the Disclosure and Transparency Rules, announces that its total issued share capital as at 31 July 2017 consists of 1,413,036,886 ordinary shares of 5 pence each in the Company ("Ordinary Shares") with one voting right per share.  The Company does not hold any Ordinary Shares in Treasury.
Upvote Downvote

 
Coats Group plc - extension of investigation scope

2017-08-01 londonstockexchange
The Financial Reporting Council (FRC) has today announced that the scope of the investigation under the Actuarial Scheme in connection with the pension schemes of various companies within the Guinness Peat Group (now renamed Coats Group plc), has been amended to include the conduct of a further Member and to extend the period under investigation, to start from 2002. 
Upvote Downvote

 
Coats restores dividend as it ties off pensions dispute

2017-07-31 telegraph.co.uk
Coats Group, the world’s largest manufacturer of thread yarn and zips, has shaken off a three-year dispute with the pensions regulator to reinstate its interim dividend amid rising profits.
Upvote Downvote

 
Coats plc 2017 Half Year results

2017-07-31 londonstockexchange
Coats Group plc ('Coats' or the 'Company'), the world's leading industrial thread manufacturer, today announces its unaudited results for the six months ended 30 June 2017.
Upvote Downvote

 
Market Report: Advertising giant WPP slumps on double downgrade

2017-07-07 telegraph.co.uk
Long-standing bull Exane BNP Paribas turned negative on advertising giant WPP, sending shares to a one-year low in intraday trade.
Upvote Downvote

 
Total Voting Rights

2017-07-03 londonstockexchange
Coats Group plc, the world's leading industrial thread manufacturer, in conformity with Rule 5.6.1 of the Disclosure and Transparency Rules, announces that its total issued share capital as at 30 June 2017 consists of 1,412,442,620 ordinary shares of 5 pence each in the Company ("Ordinary Shares") with one voting right per share.  The Company does not hold any Ordinary Shares in Treasury.
Upvote Downvote

 
Pensions Update

2017-06-26 londonstockexchange
Further to the announcements of 16 December 2016 and 17 February 2017, Coats Group plc (the "Company"), the world's leading industrial thread manufacturer, today announces that it has signed a binding Settlement agreement ("the Staveley Settlement") with the Trustee of the Staveley Industries Retirement Benefits Scheme ("Staveley").  The Company has received written assurances from the UK Pensions Regulator that its regulatory action will automatically cease in relation to Staveley under the Warning Notice that it issued to the Company in 2013 upon completion.
Upvote Downvote

 
Edison Issues Outlook on Coats Group (COA)

2017-06-13 accesswire
LONDON, UK / ACCESSWIRE / June 13, 2017 / Following the latest quarterly review, Coats Group (LSE: COA) is to enter the FTSE 250 Index with effect from 19 June. As well as signifying a strong share price performance over the last year, this concludes the company's transition phase to a strong independent entity, in our view. Valuation metrics are on a more conventional footing now and, as the market's understanding of the underlying business model increases, we sense that it is starting to anticipate faster growth rates.
Upvote Downvote

 
Total Voting Rights

2017-06-01 londonstockexchange
Coats Group plc, the world's leading industrial thread manufacturer, in conformity with Rule 5.6.1 of the Disclosure and Transparency Rules, announces that its total issued share capital as at 31 May 2017 consists of 1,411,844,363 ordinary shares of 5 pence each in the Company ("Ordinary Shares") with one voting right per share.  The Company does not hold any Ordinary Shares in Treasury.
Upvote Downvote

 
Trading Statement

2017-05-17 londonstockexchange
Coats Group plc ('Coats' or the 'Company'), the world's leading industrial thread and consumer textile crafts business, announces a trading update for the period 1 January to 30 April 2017 ahead of its Annual General Meeting later today.
Upvote Downvote

 
Total Voting Rights

2017-04-28 londonstockexchange
Coats Group plc, the world's leading industrial thread manufacturer, in conformity with Rule 5.6.1 of the Disclosure and Transparency Rules, announces that its total issued share capital as at 28 April 2017 consists of 1,411,212,101 ordinary shares of 5 pence each in the Company ("Ordinary Shares") with one voting right per share.  The Company does not hold any Ordinary Shares in Treasury.
Upvote Downvote

 
Total Voting Rights

2017-04-03 londonstockexchange
Coats Group plc, the world's leading industrial thread manufacturer, in conformity with Rule 5.6.1 of the Disclosure and Transparency Rules, announces that its total issued share capital as at 31 March 2017 consists of 1,411,130,897 ordinary shares of 5 pence each in the Company ("Ordinary Shares") with one voting right per share.  The Company does not hold any Ordinary Shares in Treasury.
Upvote Downvote

 
Annual Financial Report

2017-03-10 londonstockexchange
Coats Group plc ('Coats' or the 'Company') has today submitted to the Financial Conduct Authority's national storage mechanism its Annual Financial Report for the year ended 31 December 2016 ('Annual Report 2016'), as required by UK Listing Rule 9.6.1.
Upvote Downvote

 
Total Voting Rights

2017-03-01 londonstockexchange
Coats Group plc, the world's leading industrial thread manufacturer, in conformity with Rule 5.6.1 of the Disclosure and Transparency Rules, announces that its total issued share capital as at 28 February 2017 consists of 1,409,755,452 ordinary shares of 5 pence each in the Company ("Ordinary Shares") with one voting right per share.  The Company does not hold any Ordinary Shares in Treasury.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...